Type-2 diabetes is the original GLP-1 indication and remains the largest payer-covered market for the class. Coverage on Peptide News Digest centers on Phase 3 readouts that move prescribing — SURPASS for tirzepatide, ACHIEVE for orforglipron, the SUSTAIN series for semaglutide — and on the cardiometabolic evidence that has expanded the indication framing.
A few threads beyond the core GLP-1s: Merck's enlicitide-decanoate (PCSK9) for related lipid management, and the Foundayo (orforglipron) launch as the first small-molecule oral GLP-1 to hit the T2D market. Real-world Truveta and IQVIA data continues to track how the trial signals translate to 12-month routine care. Insulin is changing too: on September 24, 2026, the FDA approved Lilly's Onswik (insulin efsitora alfa-gobe), a basal insulin taken once a week instead of daily, based on four QWINT trials in more than 3,400 adults.
Stories here cover Phase 3 readouts, head-to-head comparisons, and payer coverage decisions. See #diabetes for the broader category and #obesity for the weight-loss-specific thread.
A UT Southwestern study published October 7, 2026 in Diabetes, Obesity and Metabolism compared 73,592 matched pairs of veterans with type 2 diabetes who started a GLP-1 drug or a DPP-4 inhibitor, an older diabetes pill, between 2006 and 2021. Over about 27 months, the GLP-1 group had a 13% lower fall rate (incidence rate ratio 0.87) and slightly less worsening on a frailty index. The link weakened in people who were already severely frail, and the observational design cannot prove the drugs caused the difference.
Zealand Pharma reported topline results on October 7, 2026 from ZUPREME-2, a 28-week randomized, double-blind, placebo-controlled Phase 2 trial of once-weekly petrelintide in 220 U.S. adults with overweight or obesity and type 2 diabetes, who started with an average BMI of 36.3 and HbA1c of 8.0%. Across three dose groups, average weight fell 7.4% to 9.2% versus 2.0% on placebo, measured as if everyone had stayed on treatment, and HbA1c fell by up to 0.65 percentage points while it rose 0.23 points on placebo. Only 1.9% of people on petrelintide stopped because of stomach side effects, versus 1.7% on placebo; the drug, partnered with Roche, entered Phase 3 in September, and Zealand plans to present full results at a scientific meeting.
Full results of OUTSTAND-2, published in Nature Medicine on Monday, October 5, 2026, come from 810 adults in China with type 2 diabetes not controlled on metformin, randomized to once-daily safiglipron (HRS-7535) 30, 60, or 90 mg or the SGLT2 inhibitor dapagliflozin 10 mg for 32 weeks. HbA1c fell 0.22 to 0.40 percentage points more on safiglipron, meeting the non-inferiority goal at every dose, and the 90 mg dose also passed the superiority test; weight loss was similar (2.35% to 4.17% on safiglipron versus 3.60% on dapagliflozin). Gastrointestinal side effects were more common on safiglipron, 3.9% to 4.0% stopped for adverse events versus 1.5% on dapagliflozin, Hengrui funded the trial, whose topline results were announced in July.
The Lancet Obstetrics, Gynaecology & Women's Health published two papers on GLP-1 drugs in women on Tuesday, September 29, 2026. A systematic review, meta-analysis, and international consensus statement led by Sarah Dib pooled seven studies covering more than 43,000 exposed women with diabetes and found no clear link to congenital anomalies, preterm birth, stillbirth, or preeclampsia; early pregnancy loss, which counted miscarriages and terminations together, was 31% more common among exposed women in two studies, a result the authors said needs caution. A companion review led by Claire Meek of the Leicester Diabetes Research Centre said the drugs' global rollout has outpaced guidance for women and cited studies in which most long-term users fell short on vitamin D, iron, and other nutrients.
Full results of Novo's REMODEL trial, first presented at the 2026 World Congress of Nephrology, were published in Nature Medicine on Thursday, October 1, 2026. The trial randomized 106 adults with type 2 diabetes and chronic kidney disease to semaglutide 1 mg weekly or placebo for 52 weeks to learn how the drug protects the kidneys. Its coprimary MRI measures of kidney oxygenation, perfusion, and inflammation did not change significantly versus placebo, but semaglutide lowered the renal artery resistive index and kept stable an MRI marker the authors link to scarring, and paired biopsies showed marked effects on the cells lining the kidney's filtering blood vessels, with fewer immune cells nearby. Urine albumin fell 40% in an exploratory analysis; Novo Nordisk funded the trial.
A retrospective study from Taipei Medical University, published in BMC Gastroenterology on Saturday, October 3, 2026, used the U.S. TriNetX health records network to compare 4,870 adults with type 2 diabetes who had a GLP-1 receptor agonist prescription in the three months before a colonoscopy with 4,870 matched adults who did not. Within 12 months, 11.0% of GLP-1 users had a repeat colonoscopy versus 8.9% of nonusers (hazard ratio 1.37), and the gap was similar after June 2023 society guidance on holding the drugs before procedures. The authors used a repeat colonoscopy as a stand-in for poor bowel preparation, which the study did not measure directly, and described the absolute difference as modest.
The American Diabetes Association and the European Association for the Study of Diabetes published their 2026 consensus report on managing type 2 diabetes in non-pregnant adults on Friday, October 2, 2026, in Diabetes Care and Diabetologia, presenting it at EASD in Milan; it updates the 2022 report. Chaired by John Buse and Melanie Davies, it calls for earlier use of glucose-lowering medicines to prevent complications and earlier use of SGLT2 inhibitors and GLP-1-based therapies to modify disease and reduce complication risk, tailored to each person's cardiovascular and kidney risk. It also sets individualized weight-management goals and gives more attention to coexisting conditions such as metabolic dysfunction-associated steatotic liver disease (MASLD).
Boehringer Ingelheim and partner Zealand Pharma reported on Thursday, October 1, 2026 that the Phase 3 SYNCHRONIZE-2 trial of survodutide, a weekly glucagon/GLP-1 receptor dual agonist, met its co-primary endpoints in 755 adults with obesity or overweight and type 2 diabetes; the results were presented at EASD and published in the New England Journal of Medicine. At 76 weeks, under the efficacy estimand, weight fell up to 13.1% on survodutide (3.6 mg and 6.0 mg doses were tested) versus 3.1% on placebo, and HbA1c fell up to 1.21 points from a baseline of 7.4% versus 0.03. Eighteen percent of survodutide patients stopped treatment because of gastrointestinal side effects, versus 1.2% on placebo, and Zealand's shares fell 11.7% in Copenhagen, according to Investing.com.
Lilly presented full results of TRIUMPH-2 at EASD on Wednesday, September 30, 2026, alongside publication in The Lancet: 1,152 adults with obesity or overweight and type 2 diabetes were randomized to weekly retatrutide 4, 9, or 12 mg or placebo for 80 weeks. Under the efficacy estimand, weight fell 12.7%, 19.1%, and 20.8% versus 4.0% with placebo, A1C fell 1.4, 1.6, and 1.5 points versus 0.2, 59.5% of people on 12 mg no longer met BMI criteria for obesity, and up to 40.0% reached an A1C below 5.7%. Discontinuation for adverse events was 3.8%, 11.6%, and 7.7% versus 4.9% on placebo, and dysesthesia, abnormal skin sensations, occurred in 4.5% to 7.3% of retatrutide patients versus 0.7%. Lilly plans to submit retatrutide to the FDA in the first quarter of 2027.
Roche announced on Tuesday, September 22, 2026 that enicepatide (CT-388), an investigational once-weekly GLP-1/GIP receptor agonist, met both primary endpoints in the randomized, placebo-controlled Phase 2 CT-388-104 trial in 447 adults with type 2 diabetes and overweight or obesity. At the highest titrated dose of 24 mg, HbA1c fell 2.65 percentage points from a baseline of 8.1%, mean weight loss was 15.5% at 48 weeks with no plateau, and 90% of patients on that dose reached an HbA1c of 6.5% or lower. Discontinuation due to adverse events was 2.0% across enicepatide arms versus 0.0% on placebo, and side effects were mostly mild-to-moderate gastrointestinal. Roche's announcement did not give placebo results for weight or HbA1c; the company plans a Phase 3 glycemic-control program and cardiovascular outcomes trials in the first half of 2027, alongside the ongoing ENITH-1 and ENITH-2 weight-management trials.
Eli Lilly announced on Thursday, September 24, 2026 that the FDA approved Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin used with diet and exercise to control blood sugar in adults with type 2 diabetes; it is not for type 1 diabetes because of an increased risk of severe hypoglycemia. Approval rests on four Phase 3 QWINT trials in more than 3,400 adults, in which efsitora met non-inferiority for A1C reduction against daily insulin glargine (QWINT-1, n=795; QWINT-4, n=730) and insulin degludec (QWINT-2, n=928; QWINT-3, n=986). Onswik will come in U-500 and U-1,000 prefilled pens delivering up to 400 and 800 units per injection, and Lilly expects U.S. availability in the coming months. It is already approved in the European Union, Mexico, and Japan.
The Lancet Diabetes & Endocrinology published Saturday August 22, 2026 the full EECOH-2 Phase 3 trial results for Xianweida's ecnoglutide (XW003), a first-in-class cAMP-biased GLP-1 receptor agonist. Mechanism: ecnoglutide preferentially activates the cAMP intracellular signaling pathway over β-arrestin recruitment when it binds the GLP-1 receptor. This biased-agonism concept selects one downstream signaling arm over the other, with the theoretical potential to separate the therapeutic effects (glucose lowering via cAMP-mediated insulin secretion) from the side-effect burden (some of which may be β-arrestin-mediated). Trial design: 52-week open-label non-inferiority Phase 3 across 52 Chinese hospitals. Adults aged 18-75 years with BMI 20-35 kg/m2, type 2 diabetes diagnosis, and elevated glucose concentrations on metformin monotherapy. Randomized to subcutaneous ecnoglutide 0.6 mg or 1.2 mg once weekly, or dulaglutide 1.5 mg once weekly (active comparator). Primary results: both ecnoglutide doses met the non-inferiority endpoint on HbA1c reduction versus dulaglutide 1.5 mg. Both doses were well tolerated with a safety profile broadly consistent with the GLP-1 receptor agonist class. Ecnoglutide is the first global cAMP-biased GLP-1 receptor agonist to reach Phase 3 publication. The biased-agonism approach could inform next-generation GLP-1 drug design and offers a differentiated tolerability profile if the concept holds in larger populations.
Eli Lilly (NYSE: LLY) plans to submit a Biologics License Application (BLA) for retatrutide (once-weekly injectable GIP/GLP-1/glucagon triple hormone receptor agonist peptide) to the FDA in Q1 2027 following the July 23, 2026 TRIUMPH-2 and TRIUMPH-3 Phase 3 readouts. TRIUMPH-2 (obesity and type 2 diabetes) enrolled 1,152 adults and documented up to 20.8% mean weight loss and 1.6 percentage point HbA1c reduction at 80 weeks. TRIUMPH-3 confirmed similar efficacy profiles across an additional patient population. Combined with the earlier readouts (TRIUMPH-1 in obesity without diabetes at 28.3% mean weight loss at 80 weeks at the 12 mg dose, and TRIUMPH-4 in obesity plus knee osteoarthritis at 28.7% weight loss with 75.8% reduction in WOMAC pain scores), the retatrutide package now covers four major indication frames with consistent efficacy. Additional TRIUMPH readouts expected across 2026 in obstructive sleep apnea, chronic lower back pain, and cardio-renal-metabolic outcomes will strengthen the label breadth. Potential FDA approval is expected in 2027-2028, positioning retatrutide to set the new weight-loss ceiling in the obesity drug class at up to 28.7% in TRIUMPH-4 and 28.3% in TRIUMPH-1 (versus tirzepatide's 25.5% and semaglutide's 15% in the current approved landscape).
Novo Nordisk's experimental CagriSema (cagrilintide plus semaglutide fixed-dose combination) reportedly failed to control blood sugar as effectively as Eli Lilly's tirzepatide (Mounjaro/Zepbound) in a head-to-head Phase 3 trial of patients with type 2 diabetes. CagriSema regulatory filing was submitted December 18, 2025 with an expected FDA decision in late 2026 for obesity indication; the type 2 diabetes head-to-head failure complicates the commercial narrative and label-expansion strategy. The trial outcome adds to the widening Lilly-Novo franchise gap documented across the Q2 2026 earnings week: Eli Lilly (NYSE: LLY) Q2 revenue reached $23 billion (+48% year-over-year) with Foundayo (orforglipron oral small-molecule GLP-1) delivering $98 million in its first fully operational commercial quarter and Mounjaro + Zepbound combined at $14.9 billion; Novo Nordisk H1 2026 sales reached 78.49 billion Danish kroner ($12.09 billion, +3% constant currency) with shares declining 5% on margin-compression concerns despite raised guidance. Investor narrative on Novo's ability to defend GLP-1 franchise economics continues to deteriorate as the amylin analog (cagrilintide) that Novo positioned as its differentiator against tirzepatide's dual GIP/GLP-1 mechanism failed to close the efficacy gap in the head-to-head setting.
Stanford University researchers presented retrospective cohort data at ENDO 2026 on June 13 from the Atropos Health Eos electronic health record dataset (~161 million patients seen in US community hospitals and academic medical centers, January 2016 to December 2023). Among adults with type 2 diabetes and no prior fractures or osteoporosis medication use, semaglutide was associated with a 15% lower fracture risk and greater weight loss versus other anti-obesity medications. Principal investigator Jairo Noreña framed the work as an early signal that semaglutide-driven weight loss may protect bone health in T2D, with prospective studies needed to confirm.
Lilly presented full Phase 3 data from the ACHIEVE program in type 2 diabetes at ADA 2026's Monday symposium. In the head-to-head ACHIEVE-3 trial, Foundayo (orforglipron) beat oral semaglutide across the primary and all key secondary endpoints, with 37.1% of patients on the highest Foundayo dose reaching HbA1c under 5.7% (normal range) versus 12.5% on the highest oral semaglutide dose tested. ACHIEVE-2 compared Foundayo to dapagliflozin; ACHIEVE-5 added it to insulin glargine. Lilly plans to submit Foundayo for FDA T2D approval by end of Q2 under the Commissioner's National Priority Voucher.
Novo Nordisk presented the full REIMAGINE 1/2/3 Phase 3 program in a Sunday symposium at ADA 2026, with simultaneous publication in The Lancet Diabetes & Endocrinology (REIMAGINE 1 and 2) and The Lancet (REIMAGINE 3). REIMAGINE 2 (n=2,713; 68 weeks) showed CagriSema 2.4/2.4 mg producing 14.2% weight loss and 1.91% HbA1c reduction versus 10.2% and 1.75% for semaglutide 2.4 mg alone. REIMAGINE 1 (n=189; 40 weeks) showed 13.8% weight loss and 1.8% HbA1c drop vs placebo. REIMAGINE 3 (n=274) showed 12.0% weight loss and a 2.33% HbA1c drop when added to basal insulin.
Innovent's DREAMS-3 Phase 3b head-to-head trial of mazdutide versus semaglutide in Chinese adults with type 2 diabetes and obesity was presented Sunday June 7 by Linong Ji of Peking University People's Hospital. On the composite primary endpoint, 48.0% of mazdutide-treated patients reached HbA1c under 7% plus at least 10% body weight reduction versus 21.0% on semaglutide. The readout is the first Phase 3 head-to-head defeat for semaglutide outside Lilly's tirzepatide series.